Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Small Cell Lung Carcinoma 10Carcinoma, Non-Small-Cell Lung 10Carcinoma, Hepatocellular 8Lung Neoplasms 6Colorectal Neoplasms 6Neoplasms 5Prostatic Neoplasms 4Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Solid Tumors 2Small Cell Lung Cancer Extensive Stage 2Sarcoma, Alveolar Soft Part 2Sarcoma 2Ovarian Neoplasms 2Mesothelioma, Malignant 2Melanoma 2Liver Neoplasms 2Extensive Stage Lung Small Cell Carcinoma 2Carcinoma, Renal Cell 2Carcinoma 2Wilms Tumor 1Vulvar Neoplasms 1Vaccinia 1Sarcoma, Clear Cell 1Rhabdomyosarcoma 1Papillary renal cell carcinoma, sporadic 1PIK3CA-Mutated Cancers 1Osteosarcoma 1

Interventions

pembrolizumab 18Specimen Handling 16Magnetic Resonance Spectroscopy 11Biopsy 11Paclitaxel 8Carboplatin 8trastuzumab deruxtecan 6Pemetrexed 6Nivolumab 6Irinotecan 6Fulvestrant 6Bevacizumab 6Radiosurgery 5Leucovorin 5Gemcitabine 5Fluorouracil 5Cetuximab 5palbociclib 4Oxaliplatin 4Letrozole 4Cisplatin 4olaparib 3durvalumab 3Taxes 3Ipilimumab 3Docetaxel 3Capecitabine 3130-nm albumin-bound paclitaxel 3sacituzumab govitecan 2ribociclib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × atezolizumab × 30 days × Clear all
NCT04449874 2026-06-02

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Genentech, Inc.

Phase 1 Active not recruiting
498 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡